HIV Clinical Trials
There are 602 actively recruiting hiv clinical trials across 80 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 4, Phase 3, Early Phase 1. Top locations include San Francisco, California, United States, New York, New York, United States, Chicago, Illinois, United States. Updated daily from ClinicalTrials.gov.
HIV Trials at a Glance
602 actively recruiting trials for hiv are listed on ClinicalTrialsFinder across 6 cities in 80 countries. The largest study group is Not Applicable with 296 trials, with the heaviest enrollment activity in San Francisco, New York, and Chicago. Lead sponsors running hiv studies include University of California, San Francisco, National Institute of Allergy and Infectious Diseases (NIAID), and Johns Hopkins University.
Browse hiv trials by phase
Top cities for hiv trials
Understanding HIV Clinical Trials
Clinical trials transformed HIV from a near-certain death sentence into a manageable chronic condition. Every antiretroviral drug in use today, from the first breakthrough with AZT in 1987 to modern single-tablet regimens like bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy), was developed through rigorous clinical research. In recent years, trials have delivered injectable long-acting treatments like cabotegravir-rilpivirine (Cabenuva), which replaces daily pills with injections every two months, and lenacapavir (Sunlenca), a twice-yearly injection. For the estimated 1.2 million people in the United States living with HIV, clinical trials continue to push toward the ultimate goals: a functional cure and a preventive vaccine.
Why Consider a Clinical Trial?
Frequently Asked Questions
Common questions about HIV clinical trials
Most HIV treatment trials do not require stopping your current medication. Many studies test new drugs as alternatives or additions to standard ART. A small number of cure-research trials involve closely monitored treatment interruptions, but these are conducted under strict safety protocols with frequent viral load testing and clear criteria for restarting medication.
Yes, many trials specifically enroll people who are virally suppressed on their current regimen. Treatment simplification trials, long-acting injectable studies, and cure research often require an undetectable viral load as an entry criterion. Having a stable and suppressed viral load can actually make you eligible for a wider range of studies.
Yes. PrEP trials and HIV vaccine trials specifically enroll HIV-negative individuals who may be at risk of acquiring HIV. These studies test new prevention methods such as long-acting injectables, implants, or vaccine candidates. Participants receive regular HIV testing and are provided with standard prevention counseling throughout the study.
Yes. Clinical trials are bound by strict federal privacy regulations (HIPAA) and additional research confidentiality protections. Your HIV status and all study-related health information are stored using coded identifiers rather than your name. Research staff are trained in confidentiality procedures and cannot share your information without your explicit consent.
No. Participating in a trial will not affect your ability to access your current HIV medications. If the trial ends or you withdraw, you will be transitioned back to your standard ART regimen. Many trials also have provisions to continue providing the study drug if it proves effective until it becomes commercially available.
Showing 1–20 of 602 trials